发明名称 Chemokine receptor antagonists and methods of use therefor
摘要 Disclosed is a method of treating a subject with a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to the subject a therapeutically effective amount of a compound represented by the following structural formula: and physiologically acceptable salts thereof. Z is a cycloalkyl or non-aromatic heterocyclic ring group fused to one or more carbocyclic aromatic rings and/or heteroaromatic rings, wherein each ring in Z is independently substituted or unsubstituted; Y is a covalent bond, -O- or -CO-; n is an integer from one to about five; X is a covalent bond or -CO-; and M is >NR2, >CR1R2; R1 is -H, -OH, an aliphatic group, -O-(aliphatic group), -SH or -S-(aliphatic group); R2 is an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group, a benzylic group, a substituted benzylic group, a non-aromatic heterocyclic group or a substituted non-aromatic heterocyclic group.
申请公布号 US2002151553(A1) 申请公布日期 2002.10.17
申请号 US20010969566 申请日期 2001.10.02
申请人 MILLENNIUM PHARMACEUTICALS, INC. 发明人 SCHWENDER CHARLES F.;MACKAY CHARLES R.;PINTO JULIA C.;NEWMAN WALTER
分类号 C07D491/044;A61K31/05;A61K31/137;A61K31/14;A61K31/216;A61K31/222;A61K31/404;A61K31/423;A61K31/428;A61K31/4427;A61K31/443;A61K31/4433;A61K31/445;A61K31/451;A61K31/4523;A61K31/4535;A61K31/454;A61K31/495;A61K31/496;A61K31/5377;A61K31/55;A61P1/04;A61P11/06;A61P17/06;A61P19/02;A61P25/00;A61P31/18;A61P37/04;A61P37/08;A61P43/00;C07D211/52;C07D401/14;C07D405/06;C07D409/06;C07D409/14;C07D493/04;C07D495/04;(IPC1-7):A61K31/496 主分类号 C07D491/044
代理机构 代理人
主权项
地址